UBS Maintains a 'Neutral' Rating on PharMerica (PMC); Any New Developments? No Sense That Bed Attrition Will Subisde
Tweet Send to a Friend
UBS maintains a 'Neutral' rating on PharMerica (NYSE: PMC), lowers PT from $13 to $10.50.
UBS analyst says, "Following up ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "Following up ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
